Duffy null-specific dosing of standard chemotherapy to avoid dose changes and neutropenic fever

You may qualify if

• Diagnosis of:; Cohort 1: MM, based on IMWG criteria12, and currently requires treatment; Cohort 2: Stage II or III TNBC, with definition per protocol Section 3.2.1 AND
• Plan for treatment, per their treating physician, or currently receiving their first cycle (see 3.3.3 for definition) of:; Cohort 1: Dara-RVd for MM; Cohort 2: A Keynote 522-based regimen of carboplatin, paclitaxel, and pembrolizumab given as the first phase of neoadjuvant treatment for TNBC.***; Participants are eligible even if the duration of carboplatin and paclitaxel goes beyond 4 cycles, or if the use of pembrolizumab, doxorubicin, and cyclophosphamide is not planned or is not certain, as long as neoadjuvant treatment starts with carboplatin-paclitaxel-pembrolizumab. This cohort will be referred to as "Keynote 522" for the remainder of the protocol. AND
• Confirmed Duffy null phenotype; Previous testing is acceptable if performed by a CLIA-approved test AND
• Age >=18 years old

You can't join if

• Inability to understand and the willingness to sign a written informed consent document
• ANC<500 within 7 days of planned start of Cycle 1 Day 1.
• Participants who have started treatment at the time of enrollment cannot have started Cycle 2 of therapy
• Participants in Cohort 2 (TNBC) cannot have received any of the pembrolizumab, doxorubicin, and cyclophosphamide portion of therapy
• Participants receiving any other investigational agents for any indication
• Another known condition or medicine with known impacts on neutrophil counts or neutrophil function